CDRH's FY 2027 Guidance Plan: PCCP Stays on the A-List and AI Software Moves Up From the B-List
Finalizing the guidance on predetermined change control plans (PCCPs) for medical devices in general is on CDRH's A-list for the second year in a row. That is from the fiscal year 2027 guidance plan that FDA's Center for Devices and Radiological Health published on October 1, 2026, covering October 2026 through September 2027. Finalizing the guidance on lifecycle management and marketing submissions for AI-enabled device software functions has moved up from last year's B-list to the A-list.
The A-list has eight items: seven targeting final guidance and one targeting draft guidance. All seven that target final guidance already have a published draft. The one planned draft is on a new subject, evidence for generative AI-enabled conversational devices for mental disorders. The Under Construction list, which covers development work, adds risk assessment for generative AI-enabled devices and select updates to the 2014 core 510(k) guidance on evaluating substantial equivalence. Comments on the plan are open until November 30.
A and B target publication this year; Under Construction is development work
The plan has three lists. The A-list prioritizes publication during the fiscal year. The B-list targets publication during the year as resources permit. The Under Construction list identifies additional development work, outside the A- and B-lists, that CDRH intends to pursue as resources permit; it is not a plan to publish during the year. Being Under Construction does not mean nothing has been published yet: some items already have a published draft. For FY 2027 the A-list has eight items, the B-list five and Under Construction four. Some items, such as ASCA, cover more than one document.
A place on the A- or B-list is not a commitment to publish. According to FDA, of the 11 items on the FY 2026 A- and B-lists, seven were published during that year: five from the A-list and two from the B-list. Under Construction items and guidance published outside the lists are not part of that count. The four items not published during FY 2026 were the final PCCP guidance for medical devices, the final AI-enabled device software functions guidance, the draft on the policy for device software functions, and the final guidance on validating tests for emerging pathogens following a section 564 declaration. The first three are on the FY 2027 plan; the last is not. For FY 2025, 11 of the 15 A- and B-list items were published.
The tables below take each FY 2027 item and show the related guidance already published and where the subject sat in the FY 2026 plan. Items that were on the FY 2026 plan but are not on this one are covered further down.
A-list (publication prioritized during the year)
| Targets | Subject (shortened) | Related guidance already published | FY 2026 plan |
|---|---|---|---|
| Final | Compliance policy for certain NIOSH-approved air-purifying respirators | Draft (Apr 2026) | A, draft |
| Final | Marketing submission and lifecycle management for AI-enabled device software functions | Draft (Jan 2025) | B, final |
| Final | Menstrual products: performance testing and labeling | Draft (Oct 2025) | A, draft |
| Final | Predetermined change control plans for medical devices | Draft (Aug 2024) | A, final |
| Final | Quality management system information for certain premarket reviews | Draft (Oct 2025) | A, draft |
| Final | Robotically-assisted surgical devices: premarket submissions | Draft (Sep 2026) | Under Construction |
| Final | Accreditation Scheme for Conformity Assessment (ASCA) program guidances | Related drafts (Sep 2024) | Not on the plan |
| Draft | Generative AI-enabled conversational devices for mental disorders: evidentiary recommendations | None found | Not on the plan |
B-list (publication targeted as resources permit)
| Targets | Subject (shortened) | Related guidance already published | FY 2026 plan |
|---|---|---|---|
| Final | User fee small business qualification and determination | Final (Jul 2025) | Not on the plan |
| Final | Pulse oximeters: performance testing, labeling and premarket submissions | Draft (Jan 2025) | Related item Under Construction (different title) |
| Final | Requests for feedback and meetings: the Q-Submission program | Final (May 2025) | Not on the plan |
| Draft | Policy for device software functions | Final (Sep 2022) | A, draft |
| Draft | Postmarket management of cybersecurity in medical devices | Final (Dec 2016) | Not on the plan |
Under Construction (development work, not a plan to publish this year)
| Targets | Subject (shortened) | Related guidance already published | FY 2026 plan |
|---|---|---|---|
| Not stated | Selecting a predicate device for a 510(k) | Draft (Sep 2023) | Under Construction |
| Not stated | Thermal effects of devices that heat or cool tissue | Draft (Mar 2024) | Under Construction |
| Not stated | Risk assessment and evidence for generative AI-enabled devices | None found | Not on the plan |
| Not stated | Select updates for the 510(k) program: evaluating substantial equivalence | Final (Jul 2014) | Not on the plan |
"Targets" is the form CDRH plans to publish next. "Related guidance already published" is the type and month of the most recent document on the same subject in FDA's guidance listings; a draft is not for implementation, and an older final on the same subject may still exist alongside it. "None found" means we could not find a corresponding published guidance, not that nothing in the field can be consulted. "Not on the plan" means the subject was not on the FY 2026 lists. Links in that column go to each document's page in FDA's guidance database (for ASCA, the draft guidance on the ASCA program itself).
All seven A-list items targeting final guidance already have a published draft
The draft PCCP guidance for medical devices in general came out in August 2024. A final PCCP guidance limited to AI-enabled device software functions already exists, but PCCPs are not only for AI. Of the 15 PCCP decisions we reviewed for September 2026 in our monthly PCCP series, five had plans we could confirm were about something other than retraining an AI model: breakpoint re-evaluation, new operating systems or connected devices, a manufacturing site change. A final general guidance would give those plans a final guidance to refer to instead of a draft. The AI-enabled device software functions guidance, also on the A-list, is the January 2025 draft covering what goes into a marketing submission and how the device is managed across its total product life cycle.
The draft quality management system guidance from October 2025 was titled "Quality Management System Information for Certain Premarket Submission Reviews." The FY 2027 plan calls it "...Premarket Application Reviews." The plan does not explain the difference.
As background, the Quality Management System Regulation (QMSR), which aligns FDA's quality system requirements with ISO 13485, took effect on February 2, 2026.
The robotically-assisted surgical devices draft was issued in September 2026 (its Federal Register notice ran on September 25), and its comment period runs to November 24. The subject was on the FY 2026 Under Construction list, reached draft stage during that year, and is now an A-list item targeting final guidance. ASCA, the program that accredits testing laboratories for conformity assessment, has had a final guidance from its 2020 pilot, followed in September 2024 by a draft for the program itself and two standards-specific drafts, one on basic safety and essential performance of electrical equipment and one on biocompatibility. The plan names this item "ASCA Program guidances," in the plural.
Two generative AI items: conversational devices for mental disorders, and risk assessment
The only A-list item targeting a draft is evidentiary recommendations for generative AI-enabled conversational devices for mental disorders. FDA's Digital Health Advisory Committee met on a closely related subject, generative AI-enabled digital mental health medical devices, on November 6, 2025. The FY 2026 Under Construction list had an item on clinical evidence for digital mental health treatment devices, including computerized behavioral therapy devices; no item by that title is on the FY 2027 plan.
The Under Construction item on risk assessment and evidence for generative AI-enabled devices has a title that suggests a broader scope. On August 18, 2026, FDA issued a discussion paper on regulating generative AI-enabled medical devices that asked for feedback on risk assessment, premarket evaluation and postmarket monitoring. The feedback deadline was October 19.
B-list: Q-Sub and small business revisions, software policy and postmarket cybersecurity
Two of the three B-list items targeting final guidance already exist as finals: the Q-Submission guidance from May 2025 and the small business qualification guidance from July 2025. The plan does not say what a revision would change. Pulse oximeters are listed under the same title as the January 2025 draft. The FY 2026 Under Construction list had a related pulse oximeter item under a different title, on assessing clinical and scientific evidence.
The two B-list items targeting drafts would both revisit final guidances. The policy for device software functions is the September 2022 final, and the plan notes that "Mobile Medical Applications" has been dropped from the title. The item was an A-list draft in FY 2026, was not published during that year, and is on the B-list for FY 2027. Postmarket management of cybersecurity dates from December 2016. The premarket cybersecurity guidance was reissued in February 2026 with "Quality System" in its title changed to "Quality Management System"; now the decade-old postmarket guidance is on the plan for revision.
Updates to the core 510(k) guidance are Under Construction
The item that stands out on the Under Construction list is "Select Updates for the 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]." The July 2014 final guidance it refers to sets out how substantial equivalence is decided in a 510(k); the title suggests work on updating parts of it. As an Under Construction item, it is not planned for publication in FY 2027. Predicate device selection and thermal effects remain on the Under Construction list from FY 2026. The predicate draft from September 2023 was titled "Best Practices for Selecting a Predicate Device"; the FY 2027 plan says "Considerations for Selecting."
Two drafts issued alongside the predicate draft in September 2023, on evidentiary expectations for 510(k) implant devices and on the use of clinical data in 510(k) submissions, were on the FY 2026 Under Construction list but are not on the FY 2027 plan. Neither are "General/Specific Intended Use," which shares its title with a 1998 guidance, and "Substantial Equivalence with Limitations." The plan gives no reasons. Absence from this year's plan does not by itself mean a document has been withdrawn, that work has stopped, or that it has been folded into a newly titled item.
How to comment
Comments on the FY 2027 plan can be submitted until November 30, 2026, at regulations.gov under docket FDA-2012-N-1021. Comments by email to CDRH-Guidance@fda.hhs.gov are accepted at any time. FDA asks for views on the relative priority of A- and B-list guidances, the policy content of planned guidances, new guidances worth developing and why, and existing guidances that should be revised or withdrawn and why.
CDRH aims, as resources permit, to finalize, withdraw, reopen the comment period of, or issue a new draft for 80% of draft guidances within three years of the comment period closing, and for all of them within five years. All 15 drafts from FY 2022 were acted on within three years. FDA says two drafts issued before October 1, 2020 still await action.
RA Craft Database's News section rounds up FDA guidance and notices every month. When guidances from the FY 2027 plan are published, they will appear in that month's roundup.
The plan was checked on October 20, 2026 against FDA's page "CDRH Proposed Guidances for Fiscal Year 2027 (FY 2027)" (posted October 1, 2026) and the PDF it links to. The FY 2026 plan is from FDA's FY 2026 page and PDF. The type and month of each related published guidance come from RA Craft Database's record of FDA guidance documents, checked against FDA's official listings on October 7, 2026, and from FDA's page for each guidance.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles